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Introduction
p53 is a tumor suppressor gene that is known to be mutated in many human cancers. 1, 2 It has been shown that overexpression of p53 by vectors including plasmid DNAs, retroviruses and adenoviruses induces cytotoxicity in many cancer cell lines in vitro. [3] [4] [5] [6] [7] [8] The mechanisms appear to involve the pathways leading to apoptosis. 6, [9] [10] [11] [12] [13] This has led to the proposal that p53 overexpression at the primary tumor site can be used for cancer gene therapy in vivo. 14, 15 Studies from many laboratories have shown that some human cancer cells when infected ex vivo with adenovirus expressing p53 and subsequently injected in immune-compromised nude mice; or direct injection of an adenovirus expressing p53 in vivo into preestablished tumor nodules inhibited the growth of human xenografts in nude mice. [16] [17] [18] [19] [20] [21] [22] [23] Since athymic mice lack a functional immune system, studies in nude mice do not address key issues pertaining to use of recombinant adenoviruses in human clinical trials. Studies in immune-competent animal models are needed in order to study the effects of the immune response to the recombinant adenoviruses and on the safety and efficacy of these vectors in gene therapy of cancer. In these investigations we have explored the use of a recombinant adenoviral vector expressing wild-type p53 in the treatment of murine renal carcinoma (Renca) cells grown in Balb/C mice. Studies reported here have shown that Renca cells are readily infected by recombinant adenoviral vectors and that Renca tumors grown in Balb/C mice can be infected with adenoviruses and that multiple administration of adenoviruses within a weeks' period are feasible and efficacious. Moreover, infection of Renca cells with AdWTp53 produces large amounts of p53, and the latter functions as a transcriptional factor, shown by the induction of p21/WAF1/Cip1 protein. We further investigated the effect of single and multiple administrations of AdWTp53 and showed that direct multiple administrations of AdWTp53 into Renca tumor nodules can significantly inhibit the tumor growth, and 30% of the animals were tumor-free at the end of the 3-month period of observation.
Since adenoviruses can only infect a small number of tumor cells within the tumor mass, we further studied if bystander effects could play a role in AdWTp53-mediated effects. We also investigated if the pre-existing adenoviral antibodies might interfere with the adenovirus-mediated transgene expression and if the administration of AdWTp53 elicits a vaccine type of effect against the Renca cells. The results presented here suggest that recombinant adenovirus-mediated expression of p53 is efficacious in inhibiting the growth of murine tumors in an immune-competent animal model and suggest that recombinant adenovirus expressing p53 could be useful in a clinical setting.
Results
Infectability of Renca cells and tumors by recombinant adenovirus expressing ␤-gal Renca cells were infected with either AdControl or Ad␤-gal (100 p.f.u. per cell) for 24 h and the expression of ␤-gal activity analyzed as described in Materials and methods. The results shown in Figure 1a indicate that there is no detectable ␤-gal activity in mock-infected cells or cells infected with a control adenovirus. However, a majority of the cells infected with Ad␤-gal display intense blue staining indicating high levels of expression of ␤-galactosidase activity.
We also investigated if Renca cells grown as allografts in immune-competent Balb/c mice can be infected with adenoviruses by direct intratumoral injection. Following injection of Renca cells (2 × 10 5 per animal) into Balb/c mice, small tumors were noted in 10 days. At this time a single injection of Ad␤-gal (10 9 p.f.u.) was given intratumorally and 2 days later the tumor was removed, fixed in formaldehyde and cells stained for the ␤-gal enzyme activity. As shown in Figure 1b , tumors that were injected with Ad␤-gal, displayed a distinct blue color which was observed using low power magnification. However, mock-infected tumors or tumors which were injected with the same dose of AdControl had no evidence of ␤-gal expression (Figure 1b) .
Histological examinations of the tumors that stained for ␤-gal activity showed that cells near the apparent needle track stained most intensely for ␤-gal expression. In addition, some cells on the periphery of the tumor also expressed ␤-gal (Figure 1c) . While, it is difficult to assess the total number of Renca cells expressing ␤-gal activity, examination of various tumor samples indicated that approximately 2-5% of the tumor cells were stained positive for ␤-gal 2 days following injection with 10 9 p.f.u. of Ad␤-gal (Figure 1c) .
When the duration of ␤-gal expression was followed over time in tumors infected with Ad␤-gal, we found that a significant blue coloration was observed in the tumors on day 1, 2 and 3 (results of day 2 are shown in Figure  1d ). However, by day 7, the tumor had lost most of the ␤-gal expression (Figure 1d ). These results indicated that Ad-mediated transgene expression in the Renca tumor is transient. We also re-injected tumors with 10 9 p.f.u. of Ad␤-gal 7 days after the initial injection. As shown in Figure 1d , following re-administration of the same dose of Ad␤-gal a marked increase in ␤-gal transgene expression was apparent 2 days following the second injection of Ad␤-gal indicating that the repeat administration of the recombinant adenovirus 1 week later results in increased transgene expression.
The efficacy and limitations of multiple administrations of Ad␤-gal were further evaluated. We were particularly interested in investigating the possible effects of immune responses to adenoviruses on subsequent transgene expression. To avoid any residual background ␤-gal activity that would obscure results we initially injected AdControl (10 9 p.f.u.) every other day for three doses. This was then followed by administration of a dose of Ad␤-gal (10 9 p.f.u.) on day 7. In these studies, ␤-gal expression was readily detected in tumors even following three prior administrations of control adenoviral infection (data not shown). These results indicate that in Balb/c mice, repeat administration after a 7-day period is feasible and leads to expression of the transgene.
Since mice bearing Renca tumors begin dying in 10-15 days, we could not study the effects of antibody production on the transgene expression post-adenovirus injection into the tumors, because the appearance of neutralizing antibodies in the blood requires at least 4-6 weeks. Therefore, to investigate the effect of pre-existing anti-adenoviral antibodies on the transgene expression, we first treated the naive animals with four weekly intramuscular injections of AdControl (10 9 p.f.u. per dose). At 6 weeks, sera from the AdControl or mock infected animals were analyzed for the presence of neutralizing antibodies to adenovirus by examining the inhibition of the binding of Ad␤-gal virus to the Renca cells in vitro in the presence or absence of different dilutions of serum. When antisera from control animals was pre-incubated with Ad␤-gal virus, no inhibition of ␤-galactosidase expression was observed at lower concentrations examined (1:1000, or 1:10 000 dilution). Some inhibition of ␤-gal expression was, however, observed at the lowest (1:100) dilution of the serum (Figure 2a ). On the other hand, sera from animals which were treated with four weekly doses of AdControl virus exhibited complete inhibition of ␤-gal expression. Even at a 1:10 000 or 1:100 000 dilution of the sera a marked inhibition was observed. These results indicate that multiple injection of adenovirus induced the production of strong neutralizing antibodies.
We next injected Renca cells subcutaneously into those Balb/C mice that contained high levels of adenoviral neutralizing antibodies or were devoid of neutralizing antibodies. When tumors formed in 10 days, the animals were then treated with a single injection of Ad␤-gal (10 9 p.f.u.) intralesionally, and ␤-gal expression was assessed 2 days later. As expected, mice without anti-adenovirus antibodies expressed high levels of ␤-gal expression (Figure 2b ). Interestingly, tumors in animals which had high titers of neutralizing antibodies also stained positive for ␤-gal expression (Figure 2b ). These results suggest that a high level of antibodies in the serum does not have a significant effect on the expression of the transgene following the prior injection of recombinant adenovirus.
Cytotoxic effects of AdWTp53 infection on Renca cells
We also investigated the expression of p53 protein in Renca cells infected with AdWTp53. While cells infected with AdControl had little or no p53 expression, with increasing doses of AdWTp53 produced correspondingly higher levels of p53 protein expression ( Figure 3 ). p53 protein produced in the cells was functional as Renca cells infected with AdWTp53 produced high levels of p21/WAF1/Cip1 protein, a p53-inducible protein [6] [7] [8] [9] ( Figure 3) .
To investigate the cytotoxicity of AdWTp53, Renca cells were exposed to increasing doses of AdWTp53 and the cytotoxicity estimated after 1 week using a sulforhodamine assay. The IC 50 for AdWTp53 was 68 p.f.u. per cell, while that of a control virus was 620 p.f.u. per cell indicating that AdWTp53 was about 10 times more cytotoxic to Renca cells than AdControl.
Next, we investigated whether p53 overexpression induces apoptosis in Renca using nucleosomal DNA analysis and DAPI staining. While uninfected or AdControl infected cells did not show the presence of a DNA ladder, cells infected with AdWTp53 exhibited a distinct DNA ladder typically associated with apoptosis ( Figure 4, left panel) . Similarly results of DAPI staining showed that while mock infection or AdControl infected cells were negative for DAPI stain, the vast majority of AdWTp53-infected Renca cells exhibited bright DAPI staining 24 h after infection (Figure 4, right panel) . These results indicate that AdWTp53 induces apoptosis in Renca cells. ited a significant inhibition of the tumor growth. By day 20, the average tumor size was only 122 mm 3 ( Figure 5 ). Although a single dose of AdWTp53 had some beneficial effect, none of the animals were tumor-free at the end of a 60-day period. We then investigated if repeating the AdWTp53 administration could induce complete regression of tumor. In these studies, animals received four doses of AdWTp53 (2.5 × 10 8 p.f.u. per dose), so that the total dose received (10 9 p.f.u.) was equivalent to that administered in the single dose study. The survival curve for the animals treated with multiple injections of AdWTp53 or AdControl is shown in Figure 6 . In mockinfected animals, the median survival was 18 days, However, the animals which received AdWTp53, had a significant increase in the median survival to 54 days ( Figure 6 ). Indeed 30% of the animals treated with multiple doses of AdWTp53 were tumor-free at the end of the 3-month period, indicating that repeat administrations of AdWTp53 can render many animals tumor-free ( Figure 6 ). Repeat doses of control adenovirus had some effect on the tumor growth, and increase in median survival to 32 days. Interestingly one out of 10 animals was also tumor-free at the end of the 3-month period in this group of animals ( Figure 4) .
In those animals which exhibited complete response to AdWTp53 treatment (three out of 10 total), we also investigated whether repeat injection of Renca cells would result in subsequent tumor formation. Animals were 
Figure 6 Effect of multiple administration of AdWTp53 on animal survival. Renca cells were injected and tumors formed as usual. Tumors were mock-infected or injected with AdWTp53 or AdControl (2.5 × 10 8 p.f.u. in 0.1 ml buffer). The vectors' administration was repeated every second day (total four doses). Animal survival was followed in the subsequent days for up to 100 days. Each group had 10 animals. Note in the group which received AdWTp53, three out of 10 animals were rendered tumorfree, and of the group which received AdControl one animal was tumorfree at the end of the 100-day period.
injected with Renca cells (2 × 10 5 cells per animal) and the tumor formation assessed. While all the naive animals developed tumors, in animals which had complete responses to AdWTp53 treatment, two out of three animals did not form tumors. Although the number of animals is limited, the observation suggested that multiple administration of AdWTp53 can induce complete tumor regressions and elicit an immune response against Renca cells.
Bystander effects perhaps play a role in in vivo effects of AdWTp53
The studies with Ad␤-gal virus suggested that only a small fraction (Ͻ5%) of the cells are infected by adenovirus (Figure 1c) . These results suggest that there is likely to be some bystander effect induced by AdWTp53 infection in order to have a substantial antitumor response. To evaluate the role of bystander effects further, Renca cells were infected in vitro with AdWTp53 and then mixed with uninfected Renca cells in different ratios. Results indicated that mixing AdWTp53-infected cells with uninfected cells did not induce substantial cytotoxicity to mock-infected cells (data not shown), suggesting that there were no bystander effects of AdWTp53 in vitro, and hence any bystander effects in vivo probably involve other systemic factors. Bystander effects of AdWTp53-infected Renca cells were also examined in vivo. AdWTp53-infected cells were mixed with uninfected cells for in different ratios, injected into Balb/c mice and tumor development followed. As shown in Figure 7 , for animals that received mock-infected cells, tumors formed in all the animals by 5 days. When the mixed population had 10% AdControl virus, all the animals had tumors by day 9. Interestingly, when the mixed population had only 10% AdWTp53-infected cells, the tumor appearance was delayed to day 22. This delay in the tumor formation was also reflected in the overall animal survival. In animals that did not receive any AdWTp53-infected cells, the median survival was 18 days. Animals that received 10% AdControl-infected cells had a median survival of 23 days. However, animals that received 10% AdWTp53-infected cells, showed a significant increase in median survival to 37 days. These results indicate that perhaps a
Figure 7 Bystander effects of AdWTp53 in vivo. Renca cells were infected with AdControl or AdWTp53 for 24 h. Virally infected cells were then mixed with uninfected cells (10% adenovirus infected with 90% uninfected) and injected into Balb/C mice. Tumor growth was followed.
Results shown are the day on which all the animals developed tumors in each group. Animal survival was also followed in each group and the median survival is described in the text.
bystander effect of AdWTp53 plays an important role in mediating the efficacy of AdWTp53 in inhibiting tumor growth.
Discussion
In this article we have shown the efficacy of a recombinant adenovirus expressing p53 (AdWTp53) in an immune-competent murine tumor model. While in recent years several reports have appeared showing the effects of such an adenovirus in inhibiting the growth of human xenografts, [16] [17] [18] [19] [20] [21] [22] [23] to our knowledge, this is the first report in which such a vector has been shown to be effective in an immune-competent mouse model.
Our ability to infect Renca cells in vivo in tumors with an adenovirus expressing ␤-galactosidase resulting in high level expression of ␤-galactosidase activity, allowed us to study the duration of transgene expression, and determine the most effective administration schedule. A single injection of Ad␤-gal into Renca tumors resulted in the transgene expression which lasted for about a week. This is not surprising considering adenoviruses do not integrate into the host genome, and the viral promoters are easily shut off by the host cells. 24 However, three injections of a control virus within a week followed by a fourth injection of Ad␤-gal still resulted in the transgene expression, indicating that multiple administrations of the recombinant adenoviruses is beneficial.
An unexpected finding was that in Balb/C mice, the presence of pre-existing neutralizing antibodies against adenovirus did not significantly alter the effectiveness of the adenovirus-mediated transgene expression, when the recombinant adenovirus was injected directly into the tumor site. In recent years it has been realized that the antibodies to the transgenes, as well as to the adenovirus backbone, could potentially limit the transgene expression. [25] [26] [27] Based on the work presented here we believe that the consequence of adenoviral antibodies should be determined in each setting. It is quite likely that a systemic administration of adenoviral vectors into the animals/patients containing high levels of neutralizing antibodies will not be feasible as the neutralizing antibodies will bind with the adenovirus, and hence prevent the subsequent transgene expression. However, in situations where the recombinant adenovirus is to be administered locally in an enclosed environment (such as prostate, bladder, lung, brain), the recombinant adenoviruses can perhaps bind and internalize into the target cells, before the anti-adenovirus antibodies can neutralize the adenovirus. Therefore, multiple administration could be feasible, even if antibodies to the adenovirus develop during the treatment. This may be particularly appealing clinically in tumors such as prostate and bladder cancer which are readily accessible by minimally invasive surgical techniques. These issues however, will eventually have to be addressed in ongoing cancer gene therapy clinical trials using recombinant adenoviral vectors.
In this report we have shown that infection of Renca cells with AdWTp53 produced high levels of p53 protein. The AdWTp53-mediated p53 protein produced was functionally active as shown by the induction of a p53-inducible gene p21/WAF1/Cip1. More importantly, p53 overexpression induced apoptosis in Renca cells. The ability of p53 to induce apoptosis is considered to be an important factor for cancer gene therapy using AdWTp53. While a single injection of AdWTp53 resulted in the inhibition of tumor growth, multiple administrations of AdWTp53 were needed to obtain complete responses. One reason for this could be the transient nature of the gene expression. Administering the vector at a certain time interval (eg every second day in the Renca model) is likely to keep the p53 levels at a higher level at least in a certain population of cells in the tumor. Moreover, injecting on different days will probably infect different populations of cells. One can also perceive a bystander effect of the first dose influencing the outcome of the second dose of the vector, and so on. Irrespective of the mechanism, these results indicate that scheduling adenovirus doses can be a critical factor in the outcome of the AdWTp53-mediated responses.
Another important observation described here is the possible bystander effect of AdWTp53 when administered in vivo and the lack of such an effect when used in vitro. Thus mixing uninfected and infected cells did not show any apparent bystander effects in vitro. However, when AdWTp53-infected cells were mixed with uninfected cells and injected into the animals, a clear influence of the infected cells was observed on the growth of uninfected Renca cells. Since Ad␤-gal studies presented suggest that only 2-5% of the cells in tumors can be infected by intratumoral injection, the apparent bystander effect might be crucial for AdWTp53 efficacy. Several mechanisms to explain the apparent bystander effect of AdWTp53 have been proposed including the influence of dead cells on the neighboring cells due to phagocytosis, and the ability of AdWTp53 to inhibit the expression of proteins such as thrombospondin and other vascular endothelial derived growth factors involved in the process of angiogenesis, thus inhibiting tumor growth. [28] [29] [30] [31] Bystander effects can also be due to the induction of specific CTL or other nonspecific immune responses against the infected tumor cells. 25, 27, 32, 33 It is conceivable that AdWTp53 could induce such responses in the Renca model described here. Preliminary work reported here also indicates that AdWTp53 can perhaps induce an immune response in such a way that the animals become refractory to the ability of challenged Renca cells to form tumors. It is important to note that even a control adenovirus devoid of any foreign transgene also has some inhibitory effect on tumor growth, indicating that the viral backbone itself in some way also activates the cytotoxic-immune cells against the virally infected cells. Interestingly, a recombinant Pox virus expressing p53 protein protected mice from a challenge with isogenic and highly immunogenic murine fibroblast tumor cells, expressing a mutant human p53 but lacking murine p53. 34 How this vaccine effect can be induced by p53 will be another very important area of future research.
In conclusion, the work presented here suggests that cancer gene therapy using a recombinant adenovirus expressing p53 is feasible and that multiple administration of AdWTp53 is more efficacious than single doses. Currently, there are a few clinical trials utilizing such a vector. While, the results from these clinical trials will eventually determine the efficacy and the limitations of using such a vector, the kinds of experiments using immune-competent mice described here will continue to shed new light on the mechanisms of adenoviral vectormediated cancer gene therapy.
Materials and methods
Cell culture Renca, a mouse kidney transformed cell line (kindly supplied by Robert Fenton, NCI, ICRF, Frederick, MD, USA), 293, and an adenovirus transformed human embryonic kidney cell line (ATCC CRL 1573, Rockville, MD, USA) were cultured in improved minimal essential medium (IMEM) (Biofluids, Rockville, MD, USA) supplemented with 2 mm glutamine (Biofluids), 2.5 g/ml fungizone (Biofluids), 100 U/ml penicillin, 100 g/ml streptomycin (100 × Pen-Strep, Biofluids) and 10% fetal bovine serum (FBS) (Biofluids).
Adenovirus vectors
The construction of adenoviral vectors containing human wild-type p53 (AdWTp53), ␤-galactosidase gene (Ad␤-gal) or devoid of any transgene (AdControl) have been previously described. 6, 9, 35 Recombinant adenoviruses were propagated in 293 cells, purified by two cesium chloride density centrifugations, titrated and stored at −70°C as described previously. 6, 9 Cytotoxicity assays Renca cells (500 cells per well) were plated in 96-well plates (500 cells per well) and incubated overnight at 37°C in IMEM containing 10% FBS. The following day the cells were incubated with increasing doses (0-10 4 p.f.u. per cell) of adenoviral vectors as described previously. 6 After incubation for 7 days at 37°C the cells were fixed with trichloroacetic acid and stained with 0.4% (wt/vol) sulforhodamine B (Sigma, St Louis, MO, USA) as described previously. 6 The OD 564 was obtained using a BioKinetics Reader EL340 (Bio-Tek Instruments, Winooski, VT, USA) and used as a measure of cell number. The IC 50 dose is the amount of adenoviral vector required to inhibit cell growth by 50%.
Animal model
) cells were injected into 10-week-old Balb/C mice. After 5-9 days palpable tumors were formed. To test the effects of AdWTp53 or AdControl, viruses were directly injected into the tumors (2.5 × 10 8 -10 9 p.f.u. in 100 l). The tumors were measured with calipers in two perpendicular diameters without the knowledge of the treatment groups. Tumor volume was calculated by assuming a spherical shape with the average tumor diameter calculated as the square root of the product of cross-sectional diameters. Tumor volumes were calculated using the formula 4/3r 3 , r being the radius of the tumor.
␤-Galactosidase expression
The presence of ␤-galactosidase gene product was determined by staining the cells with the X-gal reagent (5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside; Boehringer Mannheim, Indianapolis, IN, USA). Following transfection of Renca cells with Ad␤-gal (100 p.f.u. per cell), the cells were fixed (5 min, 4°C) in 10% formalin in phosphate-buffered saline, pH 7.4 (PBS). Cells were then stained in 5 mm K 4 Fe(CN) 6 , 5 mm K 3 Fe(CN) 6 , 2 mm MgCl 2 , and 200 g/ml X-gal solution (4 h, 37°C). Cells were photographed (×100 magnification) using a phase contrast microscope. Expression of ␤-galactosidase gene was considered positive when blue coloration in the cells was detected.
For in vivo ␤-gal staining, tumors were injected with Ad␤-gal (10 9 p.f.u.). At various time intervals, tumors were excised, fixed in 10% formalin for 4 h and treated with staining solution for 4 h as described above. Tumors were photographed using a low magnification (×5). For histological examination, stained tumors were sectioned (5 m diameter), and cells examined microscopically at various magnifications (×200), and photographed.
Western blot analysis
Renca cells (1 × 10 6 ) were plated in 10 cm dishes and incubated at 37°C with adenovirus vectors for 24 h. Cells were collected by gentle scraping. Whole cell lysates were subjected to Western blot analysis as previously described. 6 Blots were probed with 3 g/ml of antibody reactive against p53 or murine p21 (Oncogene Science, Cambridge, MA, USA), or actin protein (C4; Boehringer Mannheim).
Apoptosis assays
For nucleosomal DNA fragmentation analysis, Renca cells (2 × 10 6 ) were plated in 10 cm dishes and the next day the cells were incubated in the presence of adenovirus vectors (100 p.f.u. per cell) for 24 h. Both adherent and floating cells were collected and pelleted by centrifugation at 2000 g for 5 min (RT-6000B, Du Pont, Boston, MA, USA). Low molecular weight DNA was isolated by a modified Hirt extraction method described previously 6 and evaluated on 2.5% agarose gel electrophoresis.
For DAPI (4, 6-diamino-2-phenylindole) staining, AdWTp53-infected Renca cells were washed with PBS and harvested by trypsin. Cells (50 000) were resuspended in 50 ml of PBS. Ten milliliters of 22% bovine serum albumin (BSA) (Pierce, Rockford, IL, USA) was added to each sample and the cell/BSA suspension was pipetted into the bottom of a cytofunnel mounted with a microscope slide into the cytocentrifuge and spun at 50 g for 5 min. Slides were dried 30 min at room temperature and washed twice with PBS. Then DAPI solution (200 l of 2.5 mg/ml in 0.05 m phosphate buffer, pH 7.2) (Sigma) was added and allowed to incubate for 30 min at room temperature. The cells were washed twice more with PBS and the samples were photographed. The DAPI solution and any samples stained were stored away from light at 4°C.
Examination of bystander effects
For in vitro assays, Renca cells were plated in 10 cm dishes (10 6 cells per dish) and 24 h later infected with either AdControl (20 p.f.u. per cell) or AdWTp53 (20 p.f.u. per cell). Next day, Ad-infected cells were mixed with uninfected cells in varying ratios (0 to 100%), and plated in 96-well dishes (20 000 cells per well) and the cells were further incubated at 37°C for 5 days. Cell viability was estimated using a MTT cell proliferation assay as described previously. 36 For in vivo studies, Renca cells were infected with AdWTp53 (100 p.f.u. per cell) for 24 h. Infected cells were mixed in different ratios with uninfected cells and injected into Balb/C mice and tumor development followed subsequently.
Anti-adenoviral neutralizing antibody assays Blood was collected from the tail vein, serum prepared and heat inactivated at 60°C for 30 min. Renca cells
